In HER2+ breast cancer, the relationships between HSP90 and HER2 dimerization, trafficking, and degradation under physiological conditions or in response to trastuzumab or other HER2-targeting agents is complex and incompletely understood. Here, HSP90AA1 is linked to breast carcinoma.